CD44 Marker-Based Stem Cell Separation Workflow
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current stem cell workflows face challenges in distinguishing between parental fibroblasts, partially reprogrammed fibroblasts, and fully reprogrammed induced pluripotent stem cells (iPSCs), which hinders efficient separation and identification of pluripotent cells, particularly due to the lack of effective markers for differentiation stages.
Innovation Solution
The identification and utilization of the CD44 marker, which is highly expressed in parental and partially reprogrammed fibroblasts but negligible in fully reprogrammed iPSCs, allows for the differentiation and separation of these cell types using anti-CD44 antibodies and magnetic beads, enabling cleaner reprogrammed cell preparations and real-time monitoring of differentiation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional stem cell workflows are used without specific markers, then cell separation and identification processes are lengthy and resource-intensive, but the lack of effective markers hinders efficient differentiation and separation of cell types
Solution Approach 1:
The patent performs preliminary identification of cell pluripotency status by detecting CD44 marker expression levels before separation procedures. This preliminary action allows cells to be pre-sorted into pluripotent and non-pluripotent groups based on CD44 intensity, enabling subsequent rapid separation without time-consuming trial-and-error processes.
Solution Approach 2:
The patent utilizes changes in CD44 marker expression levels as a parameter to distinguish between pluripotent and non-pluripotent cells. By monitoring the intensity of CD44 signal, the system can identify cells at different stages of reprogramming, transforming a biochemical parameter (marker expression) into a practical separation criterion.
2Measurement precision
If multiple traditional markers are used for cell identification, then measurement complexity increases, but the ability to distinguish between parental fibroblasts, partially reprogrammed fibroblasts, and fully reprogrammed iPSCs remains insufficient
Solution Approach 1:
The patent extracts and focuses on a single critical marker (CD44) that provides sufficient discriminatory power for identifying pluripotent cells. By taking out this specific marker from the complex array of potential markers and concentrating detection resources on it, the system achieves high measurement precision without requiring multiple marker detection systems.
Solution Approach 2:
The CD44 marker serves multiple functions in the patent: it identifies parental fibroblasts, detects partially reprogrammed cells, and confirms fully reprogrammed iPSCs. This single marker performs the work of multiple traditional markers, reducing device complexity while maintaining or improving identification accuracy across different cell states.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables quick and efficient separation of fully reprogrammed cells from mixed populations, reducing the time and resources required in stem cell workflows and facilitating downstream clinical applications by providing a reliable method for identifying pluripotent cells.
Implementation Method 1
The identification and utilization of the CD44 marker, which is highly expressed in parental and partially reprogrammed fibroblasts but negligible in fully reprogrammed iPSCs, allows for the differentiation and separation of these cell types using anti-CD44 antibodies
Implementation Method 2
allows for the differentiation and separation of these cell types using anti-CD44 antibodies and magnetic beads
Data Source
AI summary
Provided herein are compositions, methods and uses that relate to or result from the identification of markers that can distinguish between cells at different stages of pluripotency. Certain embodiments provide markers that can distinguish between parental cells (i.e. differentiated cells), partially pluripotent (i.e. partially reprogrammed) and pluripotent (i.e. fully reprogrammed cells). Also provided here are uses of such differential markers, for example, in identification of cell potential, in diagnostics, in differential separation, and in creating efficient workflows that involve fewer steps and lesser time in identifying or separating a desired reprogrammed clone or cell line from a mixture of cells at various stages of pluripotency. In certain embodiments, the activity of these markers can be manipulated to influence cell potential for research or medical purposes.